Harrington Investments INC bought a new position in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,848 shares of the medical technology company’s stock, valued at approximately $999,000.

Several other large investors have also modified their holdings of the business. Hudock Capital Group LLC raised its holdings in shares of Medtronic by 0.5% during the second quarter. Hudock Capital Group LLC now owns 2,195 shares of the medical technology company’s stock worth $194,000 after purchasing an additional 11 shares during the period. Triangle Securities Wealth Management raised its holdings in shares of Medtronic by 0.3% during the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock worth $390,000 after purchasing an additional 15 shares during the period. IFC Holdings Incorporated FL grew its position in shares of Medtronic by 0.3% during the second quarter. IFC Holdings Incorporated FL now owns 5,673 shares of the medical technology company’s stock worth $501,000 after acquiring an additional 17 shares during the last quarter. Arcus Capital Partners LLC grew its position in shares of Medtronic by 0.8% during the second quarter. Arcus Capital Partners LLC now owns 3,249 shares of the medical technology company’s stock worth $288,000 after acquiring an additional 25 shares during the last quarter. Finally, Guardian Life Insurance Co. of America grew its position in shares of Medtronic by 0.6% during the first quarter. Guardian Life Insurance Co. of America now owns 5,288 shares of the medical technology company’s stock worth $426,000 after acquiring an additional 29 shares during the last quarter. 81.85% of the stock is currently owned by institutional investors.

In other news, CEO Omar Ishrak sold 140,407 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the completion of the transaction, the chief executive officer now owns 668,503 shares in the company, valued at approximately $54,569,899.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $78.03, for a total transaction of $1,248,480.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 172,407 shares of company stock valued at $13,974,223. Insiders own 0.31% of the company’s stock.

Medtronic PLC (MDT) traded down $0.86 during trading hours on Monday, hitting $81.27. 5,993,000 shares of the stock traded hands, compared to its average volume of 4,941,329. Medtronic PLC has a one year low of $69.35 and a one year high of $89.72. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. The company has a market cap of $110,006.42, a price-to-earnings ratio of 17.51, a price-to-earnings-growth ratio of 2.24 and a beta of 1.00.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The company had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. During the same quarter last year, the firm posted $1.12 EPS. The business’s revenue for the quarter was down 4.0% on a year-over-year basis. equities analysts forecast that Medtronic PLC will post 4.77 earnings per share for the current year.

Several equities analysts have recently commented on MDT shares. Zacks Investment Research lowered shares of Medtronic from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. Wells Fargo & Company lowered shares of Medtronic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $93.00 to $83.00 in a research report on Monday, October 9th. Stifel Nicolaus lowered their price target on shares of Medtronic from $91.00 to $83.00 and set a “hold” rating for the company in a research report on Monday, October 9th. SunTrust Banks restated a “buy” rating and set a $96.00 price target on shares of Medtronic in a research report on Friday, November 3rd. Finally, Leerink Swann restated a “market perform” rating and set a $85.00 price target (down previously from $88.00) on shares of Medtronic in a research report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have issued a buy rating to the company. Medtronic presently has an average rating of “Hold” and an average target price of $88.02.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/12848-shares-in-medtronic-plc-mdt-purchased-by-harrington-investments-inc/1743228.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.